

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. Please cancel claims 1-3, 5-6, 8-9, 12-13, 15-16, 23-25, and 42. Please amend claims 4, 7, 10-11, 14, 17-22, 26-28, 31, and 41 as follows.


Listing of Claims:

1-3. (Canceled)

4. (Currently amended) A compound selected from:

3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole;
3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole;
5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole; and
5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;

The compound according to claim 1 having Formula (Ih):



wherein:

~~Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or~~

a pharmaceutically acceptable salt, solvate or hydrate thereof.

5-6. (Canceled)

7. (Currently amended) The compound according to claim [[1]] 4 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8-9. (Canceled)

10. (Currently amended) The compound according to claim [[1]] 4 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

11. (Currently amended) The compound according to claim [[1]] 4 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

12-13. (Canceled)

14. (Currently amended) The compound according to claim [[1]] 4 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

15-16. (Canceled)

17. (Currently amended) The compound according to claim [[1]] 4 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

18. (Currently amended) The compound according to claim [[1]] 4 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

19. (Currently amended) The compound according to claim [[1]] 4 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

20. (Currently amended) The compound according to claim [[1]] 4 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

21. (Currently amended) The compound according to claim [[1]] 4.that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. (Currently amended) The compound according to claim [[1]] 4 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

23-25. (Canceled)

26. (Currently amended) The compound according to claim [[1]] 4 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

27. (Currently amended) A pharmaceutical composition comprising a compound according to claim [[1]] 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with a pharmaceutically acceptable carrier.

28. (Currently amended) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to claim [[1]] 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

29. (Previously Presented) The method according to claim 28 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

30. (Previously Presented) The method according to claim 28 wherein said metabolic-related disorder is atherosclerosis.

31. (Currently amended) A method of raising HDL in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to claim [[1]] 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32-40. (Canceled)

41. (Currently amended) A method of producing a pharmaceutical composition comprising admixing a compound according to claim [[1]] 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

42. (Canceled)